Rubicon Research - Form 483 with 2 procedural observations issued; no data integrity issues

On January 27, 2023, the U.S. Food and Drug Administration (FDA) issued a Form 483 during an inspection of Rubicon Research Private Limited’s facility in Satara, India. The inspection identified two procedural observations, but no data integrity issues were cited. The findings were recorded in regulatory repositories such as Redica and are consistent with FDA’s standard practice of documenting objectionable conditions during inspections.

Company filings and disclosures submitted in 2024–2025 reference additional FDA activity at Rubicon’s Thane facility, including an Establishment Inspection Report (EIR) in April 2025. These documents indicate ongoing regulatory engagement and a proactive approach to transparency by the company.

While the Satara inspection did not result in an Official Action Indicated (OAI), the issuance of a Form 483 signals the need for corrective and preventive actions (CAPA). Common consequences of such findings include delayed regulatory approvals or reputational risks, though no import alerts or warning letters have been publicly reported for Rubicon.

The absence of data integrity issues in the Satara inspection contrasts with broader industry trends, where poor data management causes Form 483 observations. Rubicon’s proactive disclosure of inspection outcomes and continued regulatory dialogue may help mitigate potential business impacts and maintain stakeholder confidence.